Nicolas Penel
Overview
Explore the profile of Nicolas Penel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
324
Citations
6177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ferraioli D, Borella F, Meurer M, Lebreton C, Penel N, Bertucci F, et al.
Int J Gynecol Cancer
. 2025 Mar;
:101692.
PMID: 40044476
Objectives: Primary ovarian leiomyosarcomas are exceptionally rare, constituting less than 1% of ovarian tumors, and they typically have a poor prognosis. The available data on the management of these tumors...
2.
Marabelle A, OMalley D, Hendifar A, Ascierto P, Motola-Kuba D, Penel N, et al.
Nat Cancer
. 2025 Feb;
6(2):253-258.
PMID: 39979665
The phase 2 trial KEYNOTE-158 ( NCT02628067 ) evaluated pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient (MSI-H/dMMR) noncolorectal tumors. With 373 participants (95% with baseline MSI/dMMR documentation) and 4.5 years of follow-up,...
3.
Seguier D, Parent P, Duterque-Coquillaud M, Labreuche J, Fromont-Hankard G, Dariane C, et al.
Eur Urol Oncol
. 2025 Jan;
PMID: 39824723
Background And Objective: It has been shown that androgen receptor pathway inhibitor (ARPIs) treatment for metastatic castration-resistant prostate cancer (mCRPC) improves overall survival rates, but ARPIs appear to be associated...
4.
Noeuveglise M, Tessier W, Barthoulot M, Decanter G, Cayeux A, Marin H, et al.
BMC Cancer
. 2024 Dec;
24(1):1550.
PMID: 39696086
Background: Soft tissue sarcomas of the extremities (E-STS) are rare and heterogeneous. Treatment combines surgery with preoperative or postoperative radiotherapy (RT) for deep, large, or high-grade tumors. We evaluate the...
5.
Colombo C, Hakkesteegt S, Cesne A, Barretta F, Blay J, Grunhagen D, et al.
Clin Cancer Res
. 2024 Dec;
31(3):603-610.
PMID: 39620931
Purpose: Three prospective observational studies (Italy, the Netherlands, and France) on active surveillance (AS) in patients with extra-abdominal desmoid-type fibromatosis support AS as a first-line approach. Identifying prognostic factors for...
6.
Srour E, Martin N, Drullion C, De Schutter C, Giroud J, Pioger A, et al.
Aging (Albany NY)
. 2024 Nov;
16(21):13201-13224.
PMID: 39560493
Aging of the epidermis partially occurs as a consequence of epidermal cell senescence, a non-proliferative state in which cells remain metabolically active and acquire changes in their secretome. We previously...
7.
Adenis A, Da Silva A, Abdelghani M, Bourgeois V, Bogart E, Turpin A, et al.
EClinicalMedicine
. 2024 Nov;
74:102470.
PMID: 39526177
Background: Early palliative care (EPC) leads to an improvement in quality of life and an unexpected survival benefit compared with oncological care for patients with metastatic lung cancer. The Early...
8.
Sweis R, Gajate P, Morales-Barrera R, Lee J, Necchi A, De Braud F, et al.
JAMA Oncol
. 2024 Sep;
10(11):1565-1570.
PMID: 39298147
Importance: The oral pan-fibroblast growth factor receptor inhibitor rogaratinib previously demonstrated encouraging safety and efficacy in a phase 1 study of patients with urothelial cancer (UC) overexpressing messenger RNA (mRNA)....
9.
Belmontes B, Slemmons K, Su C, Liu S, Policheni A, Moriguchi J, et al.
Cancer Discov
. 2024 Sep;
15(1):139-161.
PMID: 39282709
One of the most robust synthetic lethal interactions observed in multiple functional genomic screens has been the dependency on protein arginine methyltransferase 5 (PRMT5) in cancer cells with MTAP deletion....
10.
Pautier P, Italiano A, Piperno-Neumann S, Chevreau C, Penel N, Firmin N, et al.
N Engl J Med
. 2024 Sep;
391(9):789-799.
PMID: 39231341
Background: The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma. Methods: We conducted a...